Multiple studies in pancreatic cancer cells have shown that targeting CSNK2, either by pharmacological inhibition or gene silencing, leads to increased apoptosis and decreased NFKB transcription activity (Kreutzer, Ruzzene & Guerra, 2010; Giroux et al., 2009). Here, NFKB1 is linked to pancreatic neoplasm.